{"preliminary_commentary":{"by_channel":{"x_thread":20,"podcast":10,"youtube":6},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03693300\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PACIFIC 6","nct_id":"NCT03693300","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pacific-6-nct03693300. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"100-120 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.","label":"WHO/ECOG PS 0 to 1 Cohort","type":"EXPERIMENTAL"},{"description":"up to 30 participants will receive 1500 mg Durvalumab (MEDI4736) monotherapy via IV infusion q4w for up to a maximum of 24 months (up to 26 doses/cycles) with the last administration at Week 104. The study drug should be discontinued prior to 24 months if there is clinical progression or confirmed radiological progression or if there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.","label":"WHO/ECOG PS 2 Cohort","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-04-21","type":"ACTUAL"},"conditions":["Non-small Cell Lung Cancer (NSCLC)"],"enrollment":{"count":117,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab","otherNames":["MEDI4736"],"type":"DRUG"}],"last_update":"2024-06-18","lead_sponsor":"AstraZeneca","official_title":"A Phase II, Open-Label, Multi-Centre, International Safety Study of Durvalumab Following Sequential Chemotherapy and Radiation Therapy in Patients With Stage III, Unresectable Non-Small Cell Lung Cancer (PACIFIC 6)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-12-13","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Patients With Grade 3 and Grade 4 Treatment-related Adverse Events (TRAEs)","timeFrame":"Up to 6 months"}],"references":[{"citation":"Garassino MC, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D, Migliorino MR, Delmonte A, Sanchez JG, Chara Velarde LE, Bernabe R, Paz-Ares L, Perez ID, Trunova N, Foroutanpour K, Faivre-Finn C. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial. J Thorac Oncol. 2022 Dec;17(12):1415-1427. doi: 10.1016/j.jtho.2022.07.1148. Epub 2022 Aug 9.","pmid":"35961520","type":"DERIVED"}],"start_date":{"date":"2019-04-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT03693300"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pacific-6-nct03693300"}